ALK-director: Important strategic approval
With the expansion of the indication for their house dust mite pill, which now also covers the age range from 12-17 years, ALK gets access to a strategically important market segment.
BY LOUISE WENDT JENSEN
Sunday, there was great rejoice at ALK when the allergy group announced that the company’s tablet-based vaccine against house dust mite allergy, Acarizax, had expanded its approval in 12 European countries so patients in the age of 12-17 years also have access to the treatment.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
ALK: Pill gets positive mention
For abonnenter
ALK readies new EU application for allergy tablet
For abonnenter
ALK wins US approval of allergy vaccine
For abonnenter
